Nasdaq

Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome

CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with ...
Business Wire

Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presidential ...
Business Wire

Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology ...

BALANCE is a Phase 1/2, first-in-disease dose escalation and expansion study of ALPN-101 in patients with active, steroid-refractory or steroid-resistant acute GVHD. It will explore the safety, ...
Nasdaq

Crinetics Doses First Patient In Phase 2/3 BALANCE-CAH Trial Of Atumelnant

(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) has dosed the first patient in its Phase 2/3 trial of investigational drug Atumelnant for the treatment of classic congenital adrenal hyperplasia in ...